The Hematology and Oncology Clinics of three US medical centres - Dartmouth-Hitchcock Medical Center (Lebanon, NH), Pacific Shores Medical Group (Long Beach, CA) and South Carolina Oncology Associates ...
Value of caregiver ratings in evaluating the quality of life of patients with cancer. More than 500 community-based oncologists enrolled 2,342 patients with malignancies undergoing cytotoxic ...
CHICAGO -- Patients with transfusion-dependent, low-risk myelodysplastic syndromes (MDS) needed significantly fewer transfusions when treated with luspatercept (Reblozyl) for anemia compared with the ...
Capillary protein leak syndrome appears to explain fluid retention in cancer patients who receive docetaxel treatment. Two thousand three hundred seventy patients with nonmyeloid malignancies who ...
Please provide your email address to receive an email when new articles are posted on . The FDA today approved epoetin alfa-epbx, the first epoetin alfa biosimilar, for the treatment of anemia caused ...
Please provide your email address to receive an email when new articles are posted on . Hospira Inc. presented two studies that demonstrate the pharmacokinetic and pharmacodynamic equivalence of its ...
The FDA has approved Pfizer’s epoetin alfa-epbx (Retacrit), a biosimilar to epoetin alfa (Epogen), marking the first biosimilar approval of 2018 and the first biosimilar erythropoiesis-stimulating ...
BRIDGEWATER, N.J., March 7 /PRNewswire/ -- Ortho Biotech Products, L.P. today modified prescribing information for PROCRIT(R) (Epoetin alfa), following guidance from the U.S. Food and Drug ...
THOUSAND OAKS, Calif., Sept. 24 /PRNewswire/ -- Amgen (Nasdaq: AMGN) announced today that certain lots of EPOGEN® and PROCRIT® (Epoetin alfa) vials are being voluntarily recalled from specialty ...
Credit: Shutterstock Newly released safety data also show that roxadustat is associated with reduced cardiovascular risks compared with epoetin alfa. WASHINGTON—Roxadustat is superior to epoetin alfa ...
Objective: This study set out to identify the resource use and time commitment associated with treatment of anaemia with erythropoietic therapy, for both haematology/oncology clinics and patients.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results